Floatz logo

Treg-Enriched Donor Cell

Graft Vs Host Disease

Dana-Farber Cancer InstituteCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Graft Vs Host Disease cohort.

Asset / SponsorPhaseRating
Busulphan
City of Hope Medical Center
Phase 4BBB
Cyclophosphamide
City of Hope Medical Center
Phase 4BBB
Thiotepa
Memorial Sloan Kettering Cancer Center
Phase 4BBB
FILGRASTIM
City of Hope Medical Center
Phase 4BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Treg-Enriched Donor Cell is also rated in:

disease related to hematopoietic stem cell transplantDormant
CC
Indicative ·
43 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →